SCPC provides comments on the Part D provisions of the 2023 CMS Call Letter
Dear Director Seshamani:
The Senior Care Pharmacy Coalition (SCPC) appreciates the opportunity to comment on the Part D provisions of the 2023 CMS Call Letter entitled, “Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies” (the “Call Letter” or the “Proposal”), CMS 2022-0021. SCPC is the only Washington-based organization exclusively representing the interests of long-term care (LTC) pharmacies. SCPC’s membership includes 80% of all independent LTC pharmacies and our members serve one million residents daily in skilled nursing facilities and assisted living communities across the country.1 Given the distinct characteristics of the LTC patient population and the enhanced clinical responsibilities of LTC pharmacies, we offer unique perspectives on CMS’ initiatives and proposals, and particularly how Medicare Prescription Drug Benefit (“Part D”) policies and requirements impact the pharmacy community.
In brief, our comments address CMS’ proposed use pharmacy quality metrics to evaluate Medicare Prescription Drug Plans (PDPs). PDPs are insurance companies not pharmacies, and their performance should be evaluated using criteria relevant to the manner in which Part D beneficiaries evaluate insurance companies providing drug coverage, not pharmacies providing prescription drugs and related services. Our comments also address CMS’ proposed use of Pharmacy Quality Alliance (PQA) pharmacy quality measures as a component of the Star Rating metrics without appropriate qualification and without metrics specific to the LTC patient population. We are concerned that the use of PQA Measures inadvertently could skew evaluation of LTC pharmacy quality, unintentionally mislead LTC patients in selecting a LTC pharmacy and unjustifiably empower Part D Plans (PDPs) and the pharmacy benefit managers (PBMs) that administer PDPs to penalize LTC pharmacies based on inaccurate quality assessments. We also are concerned that use of the proposed opioid utilization measures in determining Star Ratings for PDPs risks undermining the quality of care for LTC patients because those measures are inappropriate to the LTC patient population due to substantially different clinical needs.
Click here to read the full letter.
Recent Posts
-
Rep. Beth Van Duyne: Congress can save seniors’ access to medications before it’s too late
Seniors in nursing homes across the country depend on round-the-clock care and medications, perhaps more than any other American patient population. In turn, the nursing homes and assisted living facilities that care for them depend on a small number of specialized long-term care (LTC) pharmacies to ensure their patients have access to the prescription meds they need.
-
Bill Aims to Offset Reimbursement Losses for Long-Term Care Pharmacies Catering to Nursing Homes
Starting in January, falling prices for costly drugs may strain long-term care pharmacies, but proposed legislation backed by advocacy groups aims to subsidize some of this loss. And nursing home advocacy groups are among those urging Congress to pass the Preserving Patient Access to Long-Term Care Pharmacies Act.
-
Drug pricing policy could jeopardize long-term care pharmacies, leaders contend
Senior living and care leaders have joined a coalition calling attention to a policy fix they say would address unintended consequences of Medicare Part D price negotiations that could shutter long-term care pharmacies.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.